Q-omics provides the consensus-scored CECR7 profile across patient tissues and cancer cell-line models. CECR7 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CECR7 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, CECR7 RNA expression shows 14,369 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, KIRC, and THYM as cancer lineages where CECR7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CECR7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CECR7 survival associations across molecular data types. CECR7 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CECR7 RNA expression–survival associations across cancer types. High CECR7 expression shows unfavorable associations in KIRP, UCEC, LIHC and STAD, but favorable associations in UVM and UCS. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for CECR7 RNA expression.
This table summarizes CECR7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CECR7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CECR7 shows lower tumor expression in KIRC, THCA, COAD and BRCA and higher tumor expression in LUAD and LUSC. The KIRC box plot shows higher CECR7 RNA expression in normal versus tumor tissue (log2 FC = −0.926, t-test p < 0.001).
This table shows molecular features associated with CECR7 in patient tissues and cancer cell lines. In patient samples, CECR7 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
